🔗 Share this article

An senior medical official has been removed from participation in a major research project concerning gender-affirming medication after accusations of preconceived views emerged.

Alleged Involvement Resulted in Study Halt

Per media accounts, Prof Jacob George, the head scientific advisor for the MHRA, voiced worries which led to the suspension of the government-backed Pathways trial in February.

The authority announced this weekend how George had recused him of participation in the trial once gender-critical online posts posted previously came to light.

Nature of Online Posts

Among one post, he described writer the Harry Potter author being a valuable figure of this era.” Separately, he stated how the refusal of basic biological fact was troubling” in relation to questions over an Olympic boxer’s sex.

This agency said that although the posts were posted prior to the role began, the official had been removed of involvement in the trial as a abundance of caution.

Details of the Halted Pathways Study

This clinical study, which was designed to assess the impact from puberty blockers for adolescents questioning their own gender identity, was scheduled to start enrolling subjects during January.

Yet, it was suspended in the following month once the regulatory body raised apprehensions regarding the welfare for young participants taking part.

• Its youngest participants were projected to start at 10 to 11 among biological females and eleven to twelve among boys.
• Its research leadership noted previously how the thorough screening procedure indicated participants would probably be of a higher age.
• However, the agency has now recommended the lowest age limit ought to be 14 because of the unknown danger” of “long-term biological harms.”

This research aimed to recruit an estimated two hundred and twenty-six adolescents over the following several years.

Context Following the Cass Review

The study was commissioned after a recommendation by the Cass review into children’s gender identity services, that determined how the robustness of the research claiming to show the benefits of this type of treatment for adolescents experiencing gender dysphoria was “poor.”

Doctor Hilary Cass, who chaired the report, once stated the findings exposed a very weak evidence base” for the usefulness of such treatments.

She noted, considering that there exist doctors, children as well as families who are convinced passionately of the helpful results, a study was the only way ahead to make sense of this.”

Expert Criticism Regarding the Action

Doctor Max Davie, a consultant paediatrician, said there was no strong medical rationale to halt the study.

“The social media posts by Prof George give a clear indication into his own opinions on the topic,” he remarked. “He is entitled to hold whatever views about this subject he chooses, however what is unacceptable is let these views to influence the fulfilment of his official role.”

He continued: “For clarity, there exists no persuasive medical basis to pause the Pathways trial. Although the professor’s own views are not the only possible explanation of the regulator’s sudden volte-face, it is the only one where we possess proof.”

Agency Statement and Future Actions

An regulatory representative said: “With every clinical trials, the MHRA’s top priority is the safety and welfare for the volunteers. In line with this duty, complicated studies are kept constantly under scrutiny while the agency maintains an active scientific dialogue alongside trial sponsors.”

“The MHRA have expert medical, scientific and regulatory specialists who work in a multidisciplinary team to deliver research-informed rulings regarding clinical trials. These individuals are continuing to engage with the university to work through the next steps in a positive manner.”

“Following the identification of social media comments posted before he took up his role, Prof Jacob George has been recused of further oversight on this clinical trial as a abundance of caution.”